Assessment of clinical benefit, cost and uptake of biosimilars versus reference biologics in immune-mediated inflammatory diseases in China

Assessment of clinical benefit, cost and uptake of biosimilars versus reference biologics in immune-mediated inflammatory diseases in China

BackgroundAs China is one of the countries with the highest recorded cases of Immune-Mediated Inflammatory Diseases (IMIDs), these diseases have also emerged as a serious public health concern. Biosimilars, potentially lower-cost versions of biologics, may improve access to more affordable yet compa...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xin Du, Xingxian Luo, Qixiang Guo, Xiaomeng Jiang, Ziling Su, Weiting Zhou, Zhongjian Wang, Jiarun Li, Yue Yang, Yi Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Series:	Frontiers in Public Health
Subjects:	immune-mediated inflammatory diseases biosimilars clinical benefit cost uptake
Online Access:	https://www.frontiersin.org/articles/10.3389/fpubh.2024.1476213/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Biosimilar biological drugs in the treatment of inflammatory bowel diseases
by: Magdalena Kaniewska, et al.
Published: (2019-12-01)

The efficacy and safety of the biosimilar product (Inflectra®) compared to the reference drug (Remicade®) in rescue therapy in adult patients with ulcerative colitis
by: Magdalena Kaniewska, et al.
Published: (2017-09-01)

Perceptions of Biosimilars Among Healthcare Providers in Saudi Arabia
by: Mohammed Alqahtani, et al.
Published: (2024-11-01)

Biosimilars, the journey has begun
by: Alba Martos-Rosa, et al.
Published: (2015-01-01)

Nonclinical Similarity of the Biosimilar Candidate ABP 938 with Aflibercept Reference Product
by: Neungseon Seo, et al.
Published: (2024-11-01)

Ustekinumab Biosimilars
by: Elena Carmona-Rocha, et al.
Published: (2024-11-01)

Iraqi Registry Data Proves Safety and Efficacy of switching to Adalimumab Biosimilar in Treating Rheumatoid Arthritis
by: Yasameen Abbas, et al.
Published: (2024-12-01)

Spanish Society of Hospital Pharmacy position paper on biosimilar medicines
by: Noemí Martínez-López de Castro, et al.
Published: (2018-07-01)

Biosimilars in Focus: Evaluating Their Role Compared to Adalimumab in Clinical Practice
by: Dorota Waz, et al.
Published: (2025-01-01)

Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52
by: Steven R. Feldman, et al.
Published: (2024-12-01)

A review of biosimilars in psoriasis: impacts on efficacy, safety, access, and a first-hand look at biosimilar cost savings within the department of veterans affairs
by: Rebecca Reese, et al.
Published: (2024-12-01)

Assessing Protein Content and Dimer Formation in the Bevacizumab Reference Product and Biosimilar Versions Marketed in Spain
by: Alexis Oliva, et al.
Published: (2024-11-01)

Clinical experience with two etanercept biosimilars in Indian patients with spondyloarthritis
by: Ashok Kumar, et al.
Published: (2017-01-01)

Biosimilar infliximab versus originator in Crohn’s disease anti-TNF-α naïve and non-naïve patients
by: Magdalena Kaniewska, et al.
Published: (2020-11-01)

Comparison of Innovative and Conventional Methods in Biosimilar Bridging Studies with Multiple References
by: Pong A, et al.
Published: (2024-12-01)

Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study
by: Narendra Maharaj, et al.
Published: (2024-12-01)

CURRENT APPROACH TO DEVELOPMENT OF BIOSIMILAR PRODUCTS CONTAINING MONOCLONAL ANTIBODIES AS AN ACTIVE SUBSTANCE – NON-CLINICAL AND CLINICAL STUDIES OF THE FIRST RUSSIAN RITUXIMAB BIOSIMILAR, ACELLBIA®
by: S. M. Alekseev, et al.
Published: (2015-04-01)

Efficacy, safety, and immunogenicity of biosimilars compared with the biologic etanercept in patients with rheumatoid arthritis: a systematic review and meta-analysis
by: Aurélio Matos Andrade, et al.
Published: (2024-11-01)

A prospective, randomized, double-blind, comparative clinical study of efficacy and safety of a biosimilar adalimumab with innovator product in patients with active rheumatoid arthritis on a stable dose of methotrexate
by: Prasad Apsangikar, et al.
Published: (2018-01-01)

Innovator ranibizumab ComparEd to Biosimilar ranibizumab in combination with Expansile gas in submaculaR HemorrhaGe: the ICEBERG study
by: Debdulal Chakraborty, et al.
Published: (2025-01-01)

Quantification of the cellular content of platelet-rich plasma harvested after injection of filgrastim versus pegfilgrastim biosimilars: a prospective, single-center, crossover study
by: Mohammadreza Abbasian, et al.
Published: (2024-12-01)

Knowledge on the Use of Biosimilars in Hematological Malignancies Amongst Health Care Workers at a Tertiary Hospital in Northeast Nigeria
by: Rufai A. Dachi, et al.
Published: (2024-07-01)

Effects of infliximab biosimilar on retinal microvasculature in Crohn’s disease patients evaluated by optical coherence tomography angiography
by: Hesham M. El Mazar, et al.
Published: (2025-01-01)

A retrospective cohort study of biosimilar rituximab therapy in pemphigus: experience from a tertiary care hospital in North India
by: Sabha Mushtaq, et al.
Published: (2024-11-01)

IS IT POSSIBLE TO USE BEVACIZUMAB BIOSIMILAR IN ALL INDICATIONS REGISTERED FOR ORIGINAL DRUG?
by: S. V. Orlov, et al.
Published: (2016-06-01)

Assessing Functional Similarity of Biosimilar ABP 654 and Ustekinumab in Samples from Patients with Crohn’s Disease
by: Foltz IN, et al.
Published: (2024-12-01)

Pooled Multicenter Safety Analysis of Lupin’s Intravitreal Biosimilar Ranibizumab (Ranieyes) in Chorioretinal Vascular Diseases
by: Debdulal Chakraborty, et al.
Published: (2024-11-01)

Wireless Antenna Sensors for Biosimilar Monitoring Toward Cyber-Physical Systems: A Review of Current Trends and Future Prospects
by: Muhammad Aziz Ul Haq, et al.
Published: (2023-01-01)

Aseptic abscess syndrome: a case report of a patient achieving remission with both infliximab originator and biosimilar administered at varied intervals
by: Federica Maria Ucci, et al.
Published: (2024-12-01)

Effect of irrigation with magnetized and ionized water on yield, nutrient uptake and water-use efficiency of winter wheat in Xinjiang, China
by: Xinyue Chen, et al.
Published: (2025-03-01)

Exploring the potential mechanisms of Urban greenspaces providing pollution Retention and cooling benefits based on three-dimensional structure of plant communities
by: Miao Yu, et al.
Published: (2024-11-01)

Ulcerative colitis: STRIDE-ing beyond symptoms with new standards
by: Shu Wen Tay, et al.
Published: (2024-02-01)

Biologics in ocular inflammatory diseases – Experience from a tertiary referral eye care center in South India
by: Kalpana Babu, et al.
Published: (2025-02-01)

Uptake and effect of radioiodine exposure on SKBR-3 cell lines
by: Miftah Irramah, et al.
Published: (2019-12-01)

Research and pilot analysis of bevacizumab repurposing potential and its impact in clinical practice
by: Antonio Ivanov, et al.
Published: (2024-12-01)

Evaluating the impact of cell-penetrating motif position on the cellular uptake of magnetite nanoparticles
by: Laura Salgado, et al.
Published: (2024-12-01)

On the linkage analysis modle of the telecom companies’ investment benefit
by: Bing XU
Published: (2017-09-01)

Silybin restores glucose uptake after tumour necrosis factor-alpha and lipopolysaccharide stimulation in 3T3-L1 adipocytes
by: Alejandra Butanda-Nuñez, et al.
Published: (2024-12-01)

Immobilization of Copper and Fluoride in Soils: Uptake by Chinese Cabbage
by: Yasin Senkondo, et al.
Published: (2024-12-01)

Mechanisms of extracellular vesicle uptake and implications for the design of cancer therapeutics
by: Stephanie R. Jackson Cullison, et al.
Published: (2024-11-01)